Cargando…
A perspective on the benefit-risk assessment for new and emerging pharmaceuticals in Japan
The universal health care system in Japan is facing a historical turning point as a result of the increasing fiscal burden, rapidly aging society, and a decreasing population. To understand the challenges and opportunities in the Japanese pharmaceutical market, which occupies one tenth of the global...
Autor principal: | Tanimoto, Tetsuya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4386774/ https://www.ncbi.nlm.nih.gov/pubmed/25848223 http://dx.doi.org/10.2147/DDDT.S62636 |
Ejemplares similares
-
Payments From Pharmaceutical Companies to Authors Involved in the Valsartan Scandal in Japan
por: Sawano, Toyoaki, et al.
Publicado: (2019) -
Pharmaceutical company payments to dermatology Clinical Practice Guideline authors in Japan
por: Murayama, Anju, et al.
Publicado: (2020) -
Severe Fever with Thrombocytopenia Syndrome: Japan under Threat from Life-threatening Emerging Tick-borne Disease
por: Crump, Andy, et al.
Publicado: (2020) -
Benefit-Risk Assessment in Pharmaceutical Research and Development
por: Sashegyi, Andreas, et al.
Publicado: (2013) -
Pharmaceutical company perspectives on current safety risk communications in Japan
por: Urushihara, Hisashi, et al.
Publicado: (2014)